Good afternoon :)
$
₹
Neuronetics Inc

Neuronetics Inc

STIM

NASDAQ
Asset Logo

Neuronetics Inc

STIM

NASDAQ
$2.921.52% (+0.04)
$
₹
$2.921.52% (+0.04)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $219.4M the stock is ranked 4205

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

11.63
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.43
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-19.62%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 4 analysts' reports

Buy
3 analysts
Hold
1 analyst
Sell
0 analyst

Analysts expect a +104.78% price upside over the next year

Current Price$2.92
Target Price$6

Company Profile

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Peers

Peers

Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
35.05
35.05
1Y Return
17.69%
17.69%
Buy Reco %
74.07
74.07
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
37.61
37.61
1Y Return
4.73%
4.73%
Buy Reco %
88.00
88.00
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
42.00
42.00
1Y Return
21.97%
21.97%
Buy Reco %
66.66
66.66
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.19
23.19
1Y Return
0.1%
0.1%
Buy Reco %
53.12
53.12
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.44
31.44
1Y Return
29.52%
29.52%
Buy Reco %
68.75
68.75

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Neuronetics Inc -11.63-
Abbott Laboratories35.053.681.99
Danaher Corporation37.612.821.26

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

37.2
-9
41.7
-7.1
34.4
-10.7
41.5
-3.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue17.4116.4518.5322.4931.9738.1037.2941.7734.4541.56
Net Income-7.87-9.83-13.34-12.66-12.67-10.12-9.04-7.15-10.79-3.43
Net Profit Margin-45.20%-59.76%-71.99%-56.29%-39.64%-26.55%-24.25%-17.13%-31.31%-8.27%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Neuronetics Inc (STIM) share price today is $2.92 as of September 9, 2026 at 1:30 AM IST. The stock touched a day high of $3.00 and a day low of $2.82.

  2. Neuronetics Inc stock trades on NASDAQ under the ticker symbol STIM.

  3. Neuronetics Inc's market capitalization is $219.44M as of September 9, 2026 at 1:30 AM IST.

  4. Neuronetics Inc's price-to-earnings (P/E) ratio is N/A as of September 8, 2026.

  5. Neuronetics Inc's price-to-book (P/B) ratio is 11.63 as of September 8, 2026.

  6. Yes, You can buy Neuronetics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Neuronetics Inc shares in three steps: 1. Search Neuronetics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Neuronetics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Neuronetics Inc (STIM) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.4199 shares at the current price of $2.92.

Loading...